First-Line Therapies for CLL

CLL10

Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia.

See the Homepage of the GCLLSG for further information (publicly available) and protocol (password protected).

CLL11

Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia.

See the Homepage of the GCLLSG for further information (publicly available) and protocol (password protected).

Therapies for relapsed/refractory CLL

CLL2O

A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic leukemia which is associated with 17p deletion or is refractory to fludarabine

See the Homepage of the GCLLSG for further information (publicly available) and protocol (password protected).

Transplantation Studies

Currently no recruiting transplantation trials.

Trials for T-PLL

T-PLL2

Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leukemia.

See the Homepage of the GCLLSG for further information (publicly available) and protocol (password protected).